



**DRUG DEVELOPMENT TOOL
21CC Transition
DDT COA #000057**

Lakshmanan Krishnamurti, MD
Professor Pediatrics
Joseph Küchenmeister/Aflac Field Force Chair
Director BMT
Aflac Cancer and Blood Disorders Center
Children's Healthcare of Atlanta
1405 Clifton Rd NE
3rd Floor, Tower 2
Atlanta, GA 30322

Dear Dr Krishnamurti:

Thank you again for agreeing to continue your ongoing clinical outcome assessment (COA) development effort under the process articulated in section 507 of the Federal Food, Drug, and Cosmetic Act as added by the 21st Century Cures Act (section 507 process). The section 507 process includes three submission types; 1) a Letter of Intent (LOI), 2) a Qualification Plan (QP), and 3) a Full Qualification Package (FQP).

As part of this transition to the section 507 process, the next step for your project, DDT COA #000057: Sickle Cell Pain Diary, would be the development of a QP. The QP is a submission that was not part of the legacy process. You may view the COA Qualification Plan outline at: www.fda.gov/media/123245/download.

Under the new process, all three stages are mandatory and all projects undergoing qualification must progress through the stages sequentially.

Please contact the CDER COA Qualification Program at COADDTQualification@fda.hhs.gov should you have any questions (refer to DDT COA #000057).

Sincerely,

Kimberly Chiu, PharmD
Regulatory Project Manager
Clinical Outcome Assessments Staff
Office of New Drugs
Center for Drug Evaluation and Research